U.S., Oct. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07205887) titled 'A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO' on Sept. 24.
Brief Summary: EYE-RES-104 is a randomized, dose-masked study of intravitreal EYE103 in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO).
The study will consist of 4 patient cohorts, with participants in each cohort randomized (1:1) to either a low dose of EYE103 via IVT or a high dose of EYE103 via IVT. 40 participants will be enrolled in each cohort. Enrollment timing for each cohort will be sequenced into specific arms of the study...